HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.

AbstractBACKGROUND AND IMPORTANCE:
Rarely, corticotrophic pituitary tumors take on an aggressive form characterized by rapid growth, invasion into local structures, compression of cranial nerves, and possible spread to distant sites. When conventional surgery, radiation therapy, and hormones fail to control progression and symptoms, alternative therapies are needed. A novel chemotherapeutic regimen of capecitabine and temozolomide (CAPTEM), originally designed in our laboratory, demonstrated dramatic antineoplastic effects against corticotrophic pituitary tumors.
CLINICAL PRESENTATION:
We present a case series of 4 patients with aggressive, adrenocorticotrophic hormone--producing pituitary tumors who had previously depleted all surgical, radiation, and hormonal therapies and were then treated with CAPTEM. Dramatic clinical improvements in neurological deficits and Cushing symptoms were evident in all patients after treatment was initiated. Confirmed by radiographic imaging, 2 of 4 patients demonstrated complete regression of disease, 1 patient had a 75% regression, and the fourth patient has ongoing stable disease for > 4.5 years at the time of this writing. Immunohistochemical analysis of patients' tumor samples showed low O-methyguanyl methyltransferase expression and adequate levels of mismatch repair enzymes (MLH-1, MSH-2, MSH-6, and PMS-2), which are important for the in vivo efficacy of CAPTEM.
CONCLUSION:
This is the first report of prolonged antitumor response to and radiographic complete remissions as a result of CAPTEM in patients with aggressive pituitary tumors who had exhausted all other therapies.
AuthorsBrad E Zacharia, Anthony P Gulati, Jeffrey N Bruce, Arthur S Carminucci, Sharon L Wardlaw, Markus Siegelin, Helen Remotti, Angela Lignelli, Robert L Fine
JournalNeurosurgery (Neurosurgery) Vol. 74 Issue 4 Pg. E447-55; discussion E455 (Apr 2014) ISSN: 1524-4040 [Electronic] United States
PMID24226425 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Deoxycytidine
  • Capecitabine
  • Dacarbazine
  • Fluorouracil
  • Temozolomide
Topics
  • ACTH-Secreting Pituitary Adenoma (drug therapy, pathology)
  • Adenoma (drug therapy, pathology)
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Capecitabine
  • Dacarbazine (administration & dosage, analogs & derivatives)
  • Deoxycytidine (administration & dosage, analogs & derivatives)
  • Female
  • Fluorouracil (administration & dosage, analogs & derivatives)
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Pituitary ACTH Hypersecretion (drug therapy, etiology, pathology)
  • Temozolomide

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: